A detailed history of Ubs Asset Management Americas Inc transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 170,615 shares of ENTA stock, worth $1.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
170,615
Previous 198,212 13.92%
Holding current value
$1.46 Million
Previous $2.57 Million 31.17%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.05 - $16.54 $277,349 - $456,454
-27,597 Reduced 13.92%
170,615 $1.77 Million
Q2 2024

Aug 13, 2024

SELL
$11.43 - $17.02 $112,894 - $168,106
-9,877 Reduced 4.75%
198,212 $2.57 Million
Q1 2024

May 15, 2024

SELL
$10.08 - $17.46 $161,078 - $279,010
-15,980 Reduced 7.13%
208,089 $3.63 Million
Q4 2023

Feb 14, 2024

SELL
$8.18 - $10.78 $451,151 - $594,549
-55,153 Reduced 19.75%
224,069 $2.11 Million
Q3 2023

Nov 13, 2023

SELL
$11.09 - $22.13 $120,348 - $240,154
-10,852 Reduced 3.74%
279,222 $3.12 Million
Q1 2023

May 15, 2023

SELL
$38.82 - $54.59 $158,696 - $223,163
-4,088 Reduced 1.39%
290,074 $11.7 Million
Q4 2022

Feb 14, 2023

BUY
$40.77 - $53.73 $10.9 Million - $14.3 Million
266,993 Added 982.71%
294,162 $13.7 Million
Q2 2022

Aug 12, 2022

BUY
$38.13 - $76.93 $324,486 - $654,674
8,510 Added 45.61%
27,169 $1.28 Million
Q1 2022

May 16, 2022

BUY
$56.06 - $74.11 $279,122 - $368,993
4,979 Added 36.4%
18,659 $1.33 Million
Q4 2021

Feb 14, 2022

BUY
$60.19 - $97.37 $81,196 - $131,352
1,349 Added 10.94%
13,680 $1.02 Million
Q2 2021

Aug 16, 2021

SELL
$43.76 - $53.11 $52,774 - $64,050
-1,206 Reduced 8.91%
12,331 $542,000
Q1 2021

May 14, 2021

BUY
$41.69 - $54.95 $287,952 - $379,539
6,907 Added 104.18%
13,537 $667,000
Q4 2020

Mar 01, 2021

SELL
$41.16 - $47.47 $184,602 - $212,902
-4,485 Reduced 40.35%
6,630 $279,000
Q3 2020

Nov 13, 2020

SELL
$43.36 - $53.53 $110,091 - $135,912
-2,539 Reduced 18.6%
11,115 $508,000
Q2 2020

Aug 14, 2020

SELL
$46.37 - $57.58 $53,835 - $66,850
-1,161 Reduced 7.84%
13,654 $685,000
Q1 2020

May 15, 2020

BUY
$40.22 - $62.0 $72,838 - $112,282
1,811 Added 13.93%
14,815 $761,000
Q4 2019

Feb 14, 2020

BUY
$57.95 - $66.61 $80,260 - $92,254
1,385 Added 11.92%
13,004 $803,000
Q3 2019

Nov 14, 2019

SELL
$60.08 - $88.17 $83,210 - $122,115
-1,385 Reduced 10.65%
11,619 $698,000
Q2 2019

Aug 15, 2019

BUY
$81.3 - $97.35 $66,259 - $79,340
815 Added 6.69%
13,004 $0
Q1 2019

May 14, 2019

BUY
$69.08 - $105.66 $239,638 - $366,534
3,469 Added 39.78%
12,189 $0
Q4 2018

Feb 13, 2019

SELL
$65.41 - $84.65 $457 - $592
-7 Reduced 0.08%
8,720 $617,000
Q3 2018

Nov 14, 2018

SELL
$85.46 - $126.37 $178,440 - $263,860
-2,088 Reduced 19.31%
8,727 $0
Q2 2018

Aug 14, 2018

BUY
$81.85 - $120.51 $294,250 - $433,233
3,595 Added 49.79%
10,815 $0
Q1 2018

May 14, 2018

BUY
$57.91 - $92.15 $180,679 - $287,508
3,120 Added 76.1%
7,220 $0
Q4 2017

Feb 09, 2018

BUY
$45.65 - $59.37 $187,165 - $243,417
4,100
4,100 $0

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $177M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.